Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;100(5):1135-1136.
doi: 10.1016/j.kint.2021.09.001. Epub 2021 Sep 9.

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Timm H Westhoff  1 , Felix S Seibert  2 , Moritz Anft  3 , Arturo Blazquez-Navarro  4 , Sarah Skrzypczyk  3 , Panagiota Zgoura  2 , Toni L Meister  5 , Stephanie Pfaender  5 , Julian Stumpf  6 , Christian Hugo  6 , Richard Viebahn  7 , Toralf Roch  4 , Ulrik Stervbo  3 , Nina Babel  8
Affiliations

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Timm H Westhoff et al. Kidney Int. 2021 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Humoral and cellular response following the third vaccination in kidney transplant recipients in whom the primary vaccination failed. Renal transplant recipients with failed seroconversion after BNT162b2 (Pfizer–BioNTech) prime-boost vaccination were subjected to the third vaccination by mRNA-1273 (Moderna). Humoral and cellular immune responses before (red) and 2 weeks after (blue) the third vaccination are presented. Enzyme-linked immunosorbent assay (ELISA) was performed for the assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein–binding antibodies, and neutralizing antibody capacity was assessed by a pseudovirus system bearing the SARS-CoV-2 S-protein. S-protein–reactive T cells were analyzed by flow cytometry following an overnight stimulation of peripheral blood mononuclear cells with overlapping peptide pools (OPPs) spanning the S-protein of SARS-CoV-2. Activation markers CD154 and CD137 were used for the assessment and quantification of S-protein–reactive T cells within CD3+ T cells. Expression levels of cytokines, interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), and interleukin 2 (IL-2), as well as the effector molecule granzyme B (GrB), were analyzed among activated CD4+ T cells by intracellular staining and flow cytometry after stimulation with OPPs spanning the whole S-protein of SARS-CoV-2. Differences between the subcohorts were analyzed using the paired, 2-sided t test. The significance threshold was set at 0.05. Box plots depict the median and first and third quartiles of a variable; the maximum length of the whiskers corresponds to 1.5× the interquartile range. (a) Titers of anti–SARS-CoV-2 S-protein–binding antibodies assessed by ELISA. (b) Neutralizing antibody titers for the SARS-CoV-2 S-protein. (c) Frequencies of S-reactive CD4+ T cells, as defined by CD154+CD137+ expression. (d) Frequencies of S-reactive CD8+ T cells, as defined by CD137 expression and cytokine production. (e) Frequencies of S-reactive follicular CD4+ T-helper cells, as defined by the expression of CXC chemokine receptor 5 (CXCR5). (f–i) Frequencies of S-reactive CD4+ T cells producing (f) GrB, (g) IFNγ, (h) IL2, and (i) TNFα. AU, arbitrary unit.
See this image and copyright information in PMC

References

    1. ERA-EDTA Council; ERACODA Working Group Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36:87–94. - PMC - PubMed
    1. Sattler A., Schrezenmeier E., Weber U.A. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131 - PMC - PubMed
    1. Miele M., Busà R., Russelli G. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant. 2021;21:2919–2921. - PMC - PubMed
    1. Kamar N., Abravanel F., Marion O. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662. - PMC - PubMed
    1. Werbel W.A., Boyarsky B.J., Ou M.T. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174:1330–1332. - PMC - PubMed

Publication types